Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celltex AdMSCs for Severe COVID-19
NCT05017298Phase 2Not yet recruiting
- Sponsor
- Celltex Therapeutics
- Start
- Nov 2024
- Primary completion
- Nov 2024
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of Celltex AdMSCs in coronavirus disease 2019 (COVID-19), sponsored by Celltex Therapeutics. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
Celltex AdMSCs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05017298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017298.